P. Grant

发表

Long-term body composition changes in antiretroviral-treated HIV-infected individuals

A. Collier, D. Kitch, T. Brown, 2016, AIDS.

Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells

S. Holmes, C. Blish, P. Grant, 2020, bioRxiv.

Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells

S. Holmes, C. Blish, P. Grant, 2020, bioRxiv.

The use of resistance testing in the management of HIV-1-infected patients

A. Zolopa, P. Grant, 2009, Current opinion in HIV and AIDS.

Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164

K. Freedberg, P. Sax, A. Zolopa, 2010, HIV clinical trials.

Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis

D. Owens, A. Zolopa, E. Bendavid, 2011, AIDS.

Improved quality of life following direct‐acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub‐Saharan Africa (the SHARED study)

P. Grant, S. Nsanzimana, N. Gupta, 2020, Journal of viral hepatitis.

Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis

H. Maecker, C. Blish, P. Grant, 2020, medRxiv.

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

A. Collier, D. Kitch, T. Brown, 2016, The Journal of infectious diseases.

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.

Jeannie S. Huang, R. Haubrich, A. Zolopa, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk factors for difficult‐to‐treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub‐Saharan Africa

P. Grant, N. Gupta, J. Serumondo, 2021, Journal of viral hepatitis.

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Laura J. Simpson, Catherine A. Blish, Angela J. Rogers, 2020, Nature Medicine.

Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic

P. Grant, P. Jagannathan, A. Subramanian, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations.

A. Zolopa, P. Grant, E. T. Richardson, 2014, Antiviral research.

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

A. Zolopa, E. Bendavid, P. Grant, 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.

M. Budoff, L. Kingsley, W. Post, 2018, Journal of clinical gastroenterology and hepatology.

Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients.

R. Dersimonian, T. Brown, P. Grant, 2015, AIDS research and human retroviruses.

Tenofovir and bone health

P. Grant, A. Cotter, 2016, Current opinion in HIV and AIDS.

Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults

D. Kitch, T. Brown, G. McComsey, 2015, HIV clinical trials.

A single-cell atlas of the peripheral immune response to severe COVID-19

Aaron J. Wilk, C. Blish, P. Grant, 2020, medRxiv.

Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia.

P. Sax, A. Zolopa, P. Grant, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

M. Lederman, A. Zolopa, P. Grant, 2010, PloS one.

A systematic review of the genetic mechanisms of dolutegravir resistance

Philip L. Tzou, J. Ioannidis, R. Shafer, 2019, The Journal of antimicrobial chemotherapy.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients

R. Shafer, P. Grant, S. Collins, 2015, Drugs.

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans

A. Zolopa, P. Grant, S. Nsanzimana, 2016, Open forum infectious diseases.

The effect of a multidisciplinary program on HAART adherence.

P. Grant, P. Frick, K. Tapia, 2006, AIDS patient care and STDs.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation

Philip L. Tzou, D. Katzenstein, R. Shafer, 2017, PloS one.

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Aaron J. Wilk, C. Blish, P. Grant, 2020, Nature Medicine.

Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma.

P. Grant, B. Pinsky, J. Waggoner, 2015, The American journal of tropical medicine and hygiene.

Encephalitis Caused by Chikungunya Virus in a Traveler from the Kingdom of Tonga

Malaya K. Sahoo, Benjamin A. Pinsky, P. Grant, 2014, Journal of Clinical Microbiology.

Fostemsavir: a first-in-class HIV-1 attachment inhibitor

M. Kozal, P. Grant, 2022, Current opinion in HIV and AIDS.

Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors

Tommy F. Liu, R. Shafer, A. Zolopa, 2010, Antimicrobial Agents and Chemotherapy.

Integrating Integrase Inhibitors Into an Antiretroviral Regimen

A. Zolopa, P. Grant, S. Collins, 2014, Current Treatment Options in Infectious Diseases.

Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.

P. Grant, S. Nsanzimana, N. Gupta, 2022, The lancet. Gastroenterology & hepatology.

Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.

J. Mukherjee, P. Grant, S. Nsanzimana, 2019, The lancet. Gastroenterology & hepatology.

Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination

Mark M. Davis, Francesco Vallania, P. Khatri, 2021, Proceedings of the National Academy of Sciences.

Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.

P. Grant, S. Nsanzimana, N. Gupta, 2022, The lancet. Gastroenterology & hepatology.

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa

E. Bendavid, P. Grant, Sabina S. Alistar, 2014, BMC Medicine.

Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164.

M. Lederman, A. Zolopa, D. Asmuth, 2012, The Journal of infectious diseases.

SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA

R. Shafer, P. Grant, B. Pinsky, 2021, Emerging infectious diseases.

Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019

D. Lyell, Y. El‐Sayed, P. Grant, 2020, American Journal of Obstetrics and Gynecology.

Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men.

J. Margolick, L. Kingsley, A. Dobs, 2019, AIDS research and human retroviruses.

Integrase inhibitors: a clinical review of raltegravir and elvitegravir.

A. Zolopa, P. Grant, 2008, Journal of HIV therapy.

Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen

D. Clifford, R. Bosch, S. Evans, 2015, Journal of NeuroVirology.

Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda

J. Mukherjee, P. Grant, S. Nsanzimana, 2020, Hepatology communications.

Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164

A. Zolopa, D. Asmuth, P. Grant, 2014, HIV clinical trials.

Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection.

C. Blish, B. Richardson, P. Grant, 2020, AIDS.

International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase

V. Calvez, A. Zolopa, Jonathan Taylor, 2010, Antimicrobial Agents and Chemotherapy.

Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

C. Farthing, A. Zolopa, J. Gallant, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection

C. Blish, B. Richardson, P. Grant, 2019, bioRxiv.

Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults

Mark M. Davis, D. Katzenstein, M. Desai, 2014, Journal of Virology.

Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores

R. Shafer, A. Zolopa, D. Kempf, 2008, Antimicrobial Agents and Chemotherapy.

, Other Protease Inhibitors of Clinical Isolates Highly Resistant to All Patterns : an Independent Cohort Analysis and Virtual Phenotypic Resistance Resistance Using Genotypic , Phenotypic , Predicting Tipranavir and Darunavir

Michel Roger, Tommy F. Liu, Robert Shafer, 2010 .

When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!

A. Zolopa, P. Grant, 2012, Current HIV/AIDS Reports.

Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: No time to lose

A. Zolopa, P. Grant, 2009, Current HIV/AIDS reports.

Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis.

A. Zolopa, P. Grant, J. Aberg, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.

A. Zolopa, P. Grant, 2010, Current opinion in investigational drugs.